126 related articles for article (PubMed ID: 24585328)
1. A word to the wise about ketamine.
Schatzberg AF
Am J Psychiatry; 2014 Mar; 171(3):262-4. PubMed ID: 24585328
[No Abstract] [Full Text] [Related]
2. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
Rotroff DM; Corum DG; Motsinger-Reif A; Fiehn O; Bottrel N; Drevets WC; Singh J; Salvadore G; Kaddurah-Daouk R
Transl Psychiatry; 2016 Sep; 6(9):e894. PubMed ID: 27648916
[TBL] [Abstract][Full Text] [Related]
3. Repeated dosing with oral racemic ketamine as a successful rescue intervention for coping with life events in recurrent major depressive disorder.
Menon V; Kale A; Balasubramanian I; Andrade C
Asian J Psychiatr; 2024 Apr; 94():103973. PubMed ID: 38402733
[No Abstract] [Full Text] [Related]
4. Fine-tuning neural excitation/inhibition for tailored ketamine use in treatment-resistant depression.
Fagerholm ED; Leech R; Williams S; Zarate CA; Moran RJ; Gilbert JR
Transl Psychiatry; 2021 May; 11(1):335. PubMed ID: 34052834
[TBL] [Abstract][Full Text] [Related]
5. Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.
Kavalali ET; Monteggia LM
Neuron; 2020 Jun; 106(5):715-726. PubMed ID: 32497508
[TBL] [Abstract][Full Text] [Related]
6. National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.
Niciu MJ; Meisner RC; Carr BR; Farooqui AA; Feifel D; Kaplin A; Kendrick EJ; Kim PM; Schneck CD; Vande Voort JL; Parikh SV
J Affect Disord; 2024 Feb; 346():221-222. PubMed ID: 37940059
[No Abstract] [Full Text] [Related]
7. Ketamine, Dissociation, and Depression: What Is "Special" About Ketamine? (Revisited).
Rizk MM; Murrough JW
Int J Neuropsychopharmacol; 2024 Jun; 27(6):. PubMed ID: 38864154
[No Abstract] [Full Text] [Related]
8. Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.
Zarate CA; Machado-Vieira R
Mol Psychiatry; 2017 Mar; 22(3):324-327. PubMed ID: 28070122
[No Abstract] [Full Text] [Related]
9. Circumspectives: the promise of ketamine.
Carlezon WA; George TP
Neuropsychopharmacology; 2015 Jan; 40(2):257-8. PubMed ID: 25502471
[No Abstract] [Full Text] [Related]
10. Electroconvulsive therapy is a standard treatment; ketamine is not (yet).
Kellner CH; Greenberg RM; Ahle GM; Liebman LS
Am J Psychiatry; 2014 Jul; 171(7):796. PubMed ID: 24980176
[No Abstract] [Full Text] [Related]
11. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
12. Ketamine and other glutamate receptor modulators for depression in adults.
Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
[TBL] [Abstract][Full Text] [Related]
14. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?
Sanacora G; Schatzberg AF
Neuropsychopharmacology; 2015 Jan; 40(2):259-67. PubMed ID: 25257213
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of ketamine response in treatment-resistant major depression.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of intranasal ketamine in major depressive disorder.
Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
[TBL] [Abstract][Full Text] [Related]
17. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
Sanacora G; Frye MA; McDonald W; Mathew SJ; Turner MS; Schatzberg AF; Summergrad P; Nemeroff CB;
JAMA Psychiatry; 2017 Apr; 74(4):399-405. PubMed ID: 28249076
[TBL] [Abstract][Full Text] [Related]
18. Ketamine as an antidepresessant: a brief research history.
Wanderer JP; Rathmell JP
Anesthesiology; 2014 Jul; 121(1):A29. PubMed ID: 24936933
[No Abstract] [Full Text] [Related]
19. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
20. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
Price RB; Iosifescu DV; Murrough JW; Chang LC; Al Jurdi RK; Iqbal SZ; Soleimani L; Charney DS; Foulkes AL; Mathew SJ
Depress Anxiety; 2014 Apr; 31(4):335-43. PubMed ID: 24668760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
